Bernstein Reduces Firm's PT on Insulet (PODD) Stock

Insulet Corporation (NASDAQ:PODD) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 9, Bernstein analyst Lee Hambright reduced the firm’s price objective on Insulet Corporation (NASDAQ:PODD)’s stock to $380 from $410, while keeping an “Outperform” rating, as reported by The Fly.

As per the firm, after a low point in September 2025, the US healthcare stocks are now performing well over the past couple of months. The firm expects better days ahead for the healthcare stocks in 2026 as the market gets more clarity on numerous macro/policy uncertainties.

Elsewhere, on January 9, Goldman Sachs analyst David Roman reduced the firm’s price objective on Insulet Corporation (NASDAQ:PODD)’s stock to $365 from $388, while keeping a “Buy” rating, as reported by The Fly. As per the analyst, after a year when fundamentals diverged from stock performance, 2026 is expected to demonstrate a return to normalized patterns, wherein organic growth explains relative valuation.

Insulet Corporation (NASDAQ:PODD) is engaged in developing, manufacturing, and selling insulin delivery systems for people with insulin-dependent diabetes.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.